Switching tristetraprolin on to turn off inflammation in COPD [ 2018 - 2020 ]

Research Grant

[Cite as]

Researchers: A/Pr Jonathan Morris Dr Nicole Verrills Prof Andrew Clark (Participant) Prof Alaina Ammit (Principal investigator)

Brief description Inflammation drives the pathogenesis of chronic obstructive pulmonary disease (COPD). We have developed a novel anti-inflammatory strategy to treat this currently untreatable disease. Our innovation is to use activators of protein phosphatase 2A to switch the molecule tristetraprolin (TTP) on and repress inflammation in COPD. Switching TTP on to turn off inflammation in COPD has proven potential to prevent irreversible damage and halt the progression of COPD.

Funding Amount $AUD 532,745.46

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]